Keystone Bio (KB) is a clinical stage, biopharmaceutical company pioneering novel disease-modifying, precision, anti-bacterial therapeutic, preventive and companion diagnostic.

KB is targeting an important, and largely unaddressed, bacterial driver of systemic chronic inflammation that significantly contributes to multiple inflammatory disease states such as heart disease and dementia/Alzheimer’s disease. This bacterial driver is Porphyromonas gingivalis (Pg). Pg produces a large number of secreted exotoxin-like virulence factors including outer membrane vesicles, gingipains, LPS and fimbriae. Over 50% of individuals have Pg by their fifth decade of life. KB’s precision bio-therapeutic, PrevEvent, is the only biologic that has been shown to eliminate and prevent recolonization in human clinical trials. The anti-inflammatory therapeutic market alone is projected to reach $130.6 billion (US) by 2026 with CAGR of 8.5% throughout the forecast period from 2018 to 2026.

Keystone Bio’s discoveries have broken the single agent, single disease paradigm by identifying the primary microbial pathogen as a single source driver of inflammation and it’s multiple NLRP3/IL-1β pathway mediated diseases including: Cardiovascular and coronary artery disease, large vessel disease/stroke, early/later stage neuro-cognitive vascular dementia, some forms of Alzheimer’s disease, T2Diabetes, aspiration pneumonia, abdominal aneurysm, rheumatoid arthritis, and orphan diseases including fatty liver disease, non-alcoholic steatohepatitis (NASH), non-smokers lung cancer and esophageal cancer.